5-Amino-2-methyl-3-(6-methylidene-2-oxopiperidin-3-yl)quinazolin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-Amino-2-methyl-3-(6-methylidene-2-oxopiperidin-3-yl)quinazolin-4-one
• 英文别名: 5-amino-2-methyl-3-(6-methylidene-2-oxopiperidin-3-yl)quinazolin-4-one
• 化学式: C₁₅H₁₆N₄O₂
• 分子量: 284.31
• InChiKey: QQRITSKIQCCFJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  87.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• USE OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE IN TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES
  申请人：Gandhi Anita

  公开号：US20140148473A1

  公开（公告）日：2014-05-29

  Provided herein are methods of using compounds and compositions for modulating lymphocytic activity, including activity of B cells and/or T cells, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.
• FORMULATIONS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE
  申请人：Celgene Corporation

  公开号：US20150196562A1

  公开（公告）日：2015-07-16

  Pharmaceutical compositions and single unit dosage forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer, an inflammatory disease and/or an immune-related disorder.
• COMBINATION THERAPY FOR CANCER
  申请人：Celgene Corporation

  公开号：US20170128448A1

  公开（公告）日：2017-05-11

  Provided herein are methods of treating, preventing and/or managing lymphomas and leukemias by administering to a patient Compound A (3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in combination with an anti-CD20 antibody or ibrutinib, or a pharmaceutically acceptable salt or solvate thereof
• COMBINATION THERAPY FOR TREATMENT OF HEMATOLOGICAL CANCERS AND SOLID TUMORS
  申请人：Celgene Corporation

  公开号：US20180193342A1

  公开（公告）日：2018-07-12

  Provided herein are methods for treating, preventing, and/or managing hematological cancers and solid tumors using combination therapy of 3-(5-amino-2-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione and checkpoint inhibitors.